Novo Nordisk signs $3.3bn deal to acquire Dicerna Pharmaceuticals
Novo Nordisk has signed a deal worth around $3.3 billion to acquire Dicerna Pharmaceuticals, a US-based biotech company focused on developing ribonucleic acid interference (RNAi) therapies. Based in Lexington, Massachusetts, Dicerna Pharmaceuticals leverages its proprietary GalXC and GalXC-Plus RNAi technologies to develop therapies to preferentially silence genes that either cause or contribute to disease. The […]